More Videos
- Reporters Barred from Ariad, Celgene, Cougar Roundtable?
- Amgen CEO To Shareholders: I Feel Your Pain, Too
- Amgen's Visit From The "Tooth Fairy" (By Way Of Root Canal?)
- Merck's Layoffs Show Pain Of Lower Drug Sales,Too Many Reps
- Pfizer "Re-Lighting" Chantix Ad Campaign For Smokers?
- Fixing Pfizer And Your Emails
- Former Merck CEO Prodding Industry On Drug Pricing
- Merck "Adapts" To Tredaptive Setback
- Regulatory "Risky Business" for Pharma & Biotech
- Amgen: Is "A" For Anemia Or Acquisition?
- Lightning Round OT: Fluor, Aqua America and More
- Cramer: AIG Chief Must Go
- The Fast Money Misfires – Friday May 9th
- Pops & Drops: Sprint, Tesoro...
- How Cramer Missed a Double
- Build-A-Trade
- Lightning Round: Juniper, Genentech, First Solar and More
- Credit Crisis: Still Cloudy?
- The Home Stretch
- The Latest Picks That Paid – Friday May 9th
- FedEx Cuts Profit Outlook, Citing Higher Fuel Costs
- Stocks Close Lower on Record Oil, AIG Loss
- White House Open to Deal on Housing Rescue Bill
- Soybeans Surge, Corn Gains After Crop Report
- HSBC: The World’s Local Bank?
- Europe's Recent Rally May Be Cut Short Next Week
- In a Weak Economy, Quirky Restaurant Ads Yield to Tried and True
- Stock Picks to Make You Stay in May
- AIG Drags on Dow; Energy Stocks Fall
- Boats, Motor Homes Get Caught in Credit Squeeze
 |
CNBC.com |
] . The purpose was to drill down into the looming court decision over whether Roche will be able to launch a competing anemia drug in the U.S. for kidney dialysis patients.
AMGN's rallying today, but fear about the ruling is part of what's pushed the shares to multi-year lows in recent days. Schoenebaum says if the judge decides that Roche can come to market, Amgen most definitely will appeal. But unless the company can win a stay at the appellate level he believes, the Roche drug reppresents a serious threat to Amgen's $3 billion-a-year kidney dialysis-related anemia drug franchise.
related content |
For every $100 million in lost sales, Bear Stearns estimates Amgen stands to lose seven cents in earnings per share. But it'll get two cents back in the presumed royalty for every $100 million in Roche sales.
You may recall from a recent post that Schoenebaum is the one who joked at the Genentech [DNA
Loading...
(%)
] analyst meeting that he might soon need to hit up DNA for a job.
Well, he's still apparently got a sense of humor about the whole situation because he kicked off the call this morning--interspersed with chuckles--by saying: "On a separate note, we all need jobs. So, if any of you are hiring please let us know. And I may not be an analyst in a few weeks for all I know. So, if any of you don't like my work, this is your opportunity to make sure you get that phone call in, too."
Self-deprecating, funny and informative. My kind of analyst. The judge in the Amgen/Roche case is expected to hand down a ruling any day now.
UPDATE: Reuters and Dow Jones are reporting that the judge today has delayed making a decision. He wants to appoint an expert or "special master" to help him investigate the matter. The two sides have 15 days to submit nominees for that task and then the judge will give the person he picks another two months to get the information he's after.
Disclosure: Schoenebaum or someone in his household owns AMGN stock. Bear Stearns makes a market in the shares and may trade AMGN options, too.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes